Argenta Discovery Ltd. and Zafgen, Inc. have entered a drug discovery collaboration to develop one of Zafgen’s therapeutics programs for obesity. Scientists from the two companies will use Argenta’s expertise in computer-aided drug design, medicinal chemistry, assay development, in vitro screening, drug metabolism and pharmacokinetics to accelerate the development of an obesity drug candidate. Dr. Thomas Hughes, Ph.D., president and chief executive officer of Zafgen, said, “We are looki...